Home
|
Inbox
|
Search
|
Speaker
Manuel Quaresma
PharmD
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial and Rare ;Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial
Session(s)
- Gastrointestinal Adverse Events with Nintedanib with Add-On Pirfenidone in Patients with I...
Sunday, May 20 11:15 AM - 1:00 PM - INSTAGE: A Randomized Trial of Nintedanib Plus Sildenafil Versus Nintedanib Alone in Patie...
Sunday, May 20 11:15 AM - 1:00 PM - Non-IPF Progressive Fibrosing Interstitial Lung Disease (PF-ILD): The Patient Journey [Boa...
Sunday, May 20 11:15 AM - 1:00 PM - Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF)...
Sunday, May 20 11:15 AM - 1:00 PM - Current Treatment of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease...
Monday, May 21 2:15 PM - 4:15 PM
|
Home
|
Inbox
|
Search
|